Stalfort John A III 4
4 · Acumen Pharmaceuticals, Inc. · Filed Jul 8, 2021
Insider Transaction Report
Form 4
Stalfort John A III
Director
Transactions
- Conversion
Series A-1 Preferred
2021-07-06−130,180→ 0 total→ Common Stock (130,180 underlying) - Conversion
Common Stock
2021-07-06+130,180→ 137,324 total - Conversion
Common Stock
2021-07-06+131,595→ 131,595 total(indirect: See footnote) - Conversion
Series B Preferred
2021-07-06−131,595→ 0 total(indirect: See footnote)→ Common Stock (131,595 underlying) - Purchase
Common Stock
2021-07-06$16.00/sh+35,000$560,000→ 172,324 total
Footnotes (2)
- [F1]On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and each share of Series B Convertible Preferred Stock converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.